Vaxcyte, Inc. (PCVX)
| Market Cap | 7.65B +71.9% |
| Revenue (ttm) | n/a |
| Net Income | -946.53M |
| EPS | -6.91 |
| Shares Out | 144.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,917,133 |
| Open | 50.82 |
| Previous Close | 51.48 |
| Day's Range | 50.82 - 53.39 |
| 52-Week Range | 28.64 - 65.00 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 88.25 (+66.48%) |
| Earnings Date | May 6, 2026 |
About PCVX
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PCVX stock is "Strong Buy." The 12-month stock price target is $88.25, which is an increase of 66.48% from the latest price.
News
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
The company said, “With the recent completion of OPUS-3 enrollment, our OPUS-1, OPUS-2 and OPUS-3 adult Phase 3 trials are now fully enrolled, and we remain on track to deliver
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte Transcript: 25th Annual Needham Virtual Healthcare Conference
Upcoming 12–15 months will see pivotal data from adult and infant VAX-31 studies, with a BLA filing targeted by end of next year and potential approval in 2028. Market growth is driven by expanded adult vaccination and global recommendations, while strong financials support continued development.
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
Vaxcyte (PCVX) announced the completion of enrollment in the VAX-31 OPUS-1 Phase 3 pivotal, noninferiority trial with approximately 4,000 participants and the OPUS-2 Phase 3 trial evaluating VAX-31 co...
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capva...
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
The company states: “Vaxcyte (PCVX) announced the publication of results from the positive VAX-31 adult Phase 1/2 clinical study in the journal The Lancet Infectious Diseases. The study evaluated the
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data f...
Vaxcyte Transcript: Leerink Global Healthcare Conference 2026
The company is advancing its 31-valent pneumococcal vaccine, VAX-31, through pivotal phase III trials with results expected by mid-2025 and a BLA filing targeted by year-end 2025. A novel Group A Strep vaccine will enter clinical trials in 2024, addressing a major unmet need.
Vaxcyte Transcript: TD Cowen 46th Annual Health Care Conference
VAX-31, a 31-valent pneumococcal vaccine, is advancing through pivotal phase 3 trials with key data expected this year and next. Innovative conjugation technology enables broader serotype coverage and improved immune responses, while regulatory and market dynamics favor expanded adult vaccination. Group A Strep vaccine development and global market growth further strengthen the outlook.
Vaxcyte price target raised to $89 from $85 at BTIG
BTIG raised the firm’s price target on Vaxcyte (PCVX) to $89 from $85 and keeps a Buy rating on the shares after its Q4 results. The details have led to
Vaxcyte price target lowered to $133 from $134 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Vaxcyte (PCVX) to $133 from $134 and keeps a Buy rating on the shares. The firm, which sees “no surprises”
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Vaxcyte (PCVX) to $67 from $38 and keeps a Neutral rating on the shares. Since coverage initiation, shares have risen steadily due
Vaxcyte price target raised to $75 from $50 at TD Cowen
TD Cowen analyst Tara Bancroft raised the firm’s price target on Vaxcyte (PCVX) to $75 from $50 and keeps a Buy rating on the shares. The firm said Vaxcyte enters
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
“In 2025, we made meaningful progress across clinical development, regulatory engagement and commercial manufacturing readiness as we advanced our broad-spectrum pneumococcal conjugate vaccine franchi...
Vaxcyte Earnings Call Transcript: Q4 2025
Strong clinical and operational progress in 2025, with late-stage VAX-31 trials advancing and a robust financial position supporting expansion. Manufacturing readiness and resumed pipeline development position the company for a catalyst-rich 2026–2027.
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, To...
Vaxcyte Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Pneumococcal vaccine innovation is driving expansion into global adult and pediatric markets, with VAX-31 showing best-in-class data and aiming for broad serotype coverage. Strong financials support a pivotal phase 3 program and potential 2028 launch.
Vaxcyte doses first participants in OPUS-3 trial
Vaxcyte (PCVX) announced that the first participants were dosed in the OPUS-3 Phase 3 trial evaluating VAX-31, the company’s next-generation 31-valent pneumococcal conjugate vaccine candidate, in adul...
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth qu...
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside ...
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten pu...
Vaxcyte 11M share Spot Secondary priced at $50.00
The deal size was increased to $550M in common stock from $500M in common stock. BofA, Jefferies, Leerink, Evercore ISI and Guggenheim acted as joint book running managers for the
Vaxcyte Announces Pricing of $550 Million Public Offering
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of commo...